TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01637831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
Study: NCT02309853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual and tactile scanning training
Description: 20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uni-modal visual scanning training
Description: 20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
Study: NCT00698087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPL-Adjuvanted recombinant hepatitis B vaccine
Description: Intramuscular injection, 2 or 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPL-Adjuvanted recombinant hepatitis B vaccine
Description: Intramuscular injection, 2 or 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 2 or 3 doses
Study: NCT01974076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + CBT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + CBT
Study: NCT01376206

Intervention type: DRUG
Intervention: Fluticasone
Description: Collection of safety data
Study: NCT00466843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Description: ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
Study: NCT03566888

Intervention type: DEVICE
Intervention: Blood pressure assessment
Description: Validation of an automated blood pressure device
Study: NCT02746146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic use of a prognostic score
Description: The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
Study: NCT03173313

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular permissive hypothermia as an adjunct to PCI
Description: Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular permissive hypothermia as an adjunct to PCI
Description: Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
Study: NCT05898685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intermittent normoxia
Description: The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
Study: NCT03046758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A combination of fosfomycin, metronidazole and GM-CSF i.p.
Description: All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
Study: NCT00753571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cistanche Total Glycosides
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cistanche Total Glycosides
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2
Study: NCT01065597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonconvulsive electrotherapy
Description: An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
Study: NCT02579837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos 200Tx
Description: non-mydriatic ultra-widefield (UWF) retinal imaging device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss Cirrus
Description: optical coherence tomographer (OCT)
Study: NCT00769210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg tablet
Study: NCT01689519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib supplied as tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib supplied as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib supplied as tablets
Study: NCT03082430

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous PRP.
Description: one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
Study: NCT01021527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection
Study: NCT00734175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H6N1 Teal HK 97/AA ca recombinant vaccine
Description: Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
Study: NCT00183638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based tailored prevention messages
Description: Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
Study: NCT02985372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT01631773

Intervention type: GENETIC
Intervention: microRNA
Description: Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.

Intervention type: GENETIC
Intervention: microRNA
Description: Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
Study: NCT03725137

Intervention type: OTHER
Intervention: Analysis of T-lymphocytes
Description: Analysis of T-lymphocytes regarding the development of cognitive function after stroke
Study: NCT02272660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium
Description: The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
Study: NCT03389620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
Study: NCT01164930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 8-week ACT group
Study: NCT00183638

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored messages
Description: The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
Study: NCT03692949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: One dose administered (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: One dose administered SC
Study: NCT03285191

Intervention type: OTHER
Intervention: Numerical rating scale
Description: Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).

Intervention type: OTHER
Intervention: Numerical rating scale
Description: Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).

Intervention type: OTHER
Intervention: Real-time data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
Study: NCT03169010

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.
Study: NCT00755378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01937819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART arm
Description: The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
Study: NCT02369120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal care by GP
Description: Patients will follow GP advice including NSAID medication if needed
Study: NCT01245439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
Study: NCT01409512

Intervention type: PROCEDURE
Intervention: ECG recording
Description: At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
Study: NCT00591838

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study: NCT03673943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTATATE
Description: Detection of somatostatin positive lesions in NET
Study: NCT03522519

Intervention type: BEHAVIORAL
Intervention: Real world performance of physical activity and arm use
Description: Patients will be assessed by using movement sensors and standard clinical assessments
Study: NCT02770196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-CSA plus Nutrition Education
Description: Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-CSA plus Nutrition Education
Description: Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-CSA plus Nutrition Education
Description: Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-CSA plus Nutrition Education
Description: Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
Study: NCT02932358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Family Visitation Model (FFVM)
Description: Visitation to ICU patients allowed during the period of 12 consecutive hours per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Family Visitation Model (RFVM)
Description: Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
Study: NCT01080599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Study: NCT03045900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shaded bulk-fill resin composite
Description: Dental bulk-fill resin composite with shades A1, A2, A3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shaded bulk-fill resin composite
Description: Dental bulk-fill resin composite with shades A1, A2, A3
Study: NCT03413319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Solution for infusion
Study: NCT02508844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx®
Description: probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
Study: NCT00560014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and canola oil
Description: Canola oil 1 tablespoon BID Arginine 9.0grams BID

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega and Arginine
Description: Arginine 9.0 grams BID Coromega dose based on weight
Study: NCT04806256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System
Description: This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine intervention
Description: The routine intervention without CDSS is also the clinically common intervention at present.
Study: NCT04593719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment
Description: The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
Study: NCT02727764

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
Study: NCT03489317

Intervention type: DRUG
Intervention: Metformin
Description: Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.

Intervention type: DRUG
Intervention: Metformin
Description: Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study: NCT03169010

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.
Study: NCT00423410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPC2407 (crinobulin)
Description: IV infusion 1 to 4 hours
Study: NCT01515306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab (IMC-1121B)
Description: ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
Study: NCT01109758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg
Study: NCT01515306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab (IMC-1121B)
Description: ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
Study: NCT00878917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2 % eye drops solution
Description: 1 drop into eye(s) three times a day for the duration of each treatment phase
Study: NCT01021527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection